Overview

A Study to Investigate the Exposure and Safety and Tolerability of a Single Dose of FG-4592 in Subjects With Moderately Diminished Liver Function Compared to Those With Normal Liver Function

Status:
Completed

Trial end date:
2013-12-01

Target enrollment:

Participant gender:

Summary

The effect of moderately diminished liver function on the exposure, safety and tolerability of a single dose of FG-4592 is studied in male and female subjects. The results are compared to the data gained from subjects with normal liver function.

Phase:

Phase 1

Details

Lead Sponsor:

Astellas Pharma Europe B.V.

Collaborator:

FibroGen